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Nogo-A–speciﬁc antibody
treatment enhances sprouting and
functional recovery after cervical
lesion in adult primates
Patrick Freund1,5, Eric Schmidlin1,5, Thierry Wannier1,2,5,
Jocelyne Bloch3, Anis Mir4, Martin E Schwab2 &
Eric M Rouiller1
In rodents, after spinal lesion, neutralizing the neurite growth
inhibitor Nogo-A promotes axonal sprouting and functional
recovery. To evaluate this treatment in primates, 12 monkeys
were subjected to cervical lesion. Recovery of manual dexterity
and sprouting of corticospinal axons were enhanced in monkeys
treated with Nogo-A–speciﬁc antibody as compared to monkeys
treated with control antibody.
After injury, the adult mammalian central nervous system has only a
limited capacity to repair itself. Transected nerve ﬁbers do not
spontaneously regrow, in part because of the effects of myelin-
associated neurite growth inhibitors such as Nogo-A1,2. After section
of the corticospinal tract in adult rats, neutralizing Nogo-A with
monoclonal antibodies leads to enhancement of axonal regrowth
and compensatory sprouting, accompanied by increased motor
recovery2–4. The neutralization of Nogo-A represents a promising
approach for therapy after lesion if its efﬁcacy can be demonstrated in
primates. First, the general organization of the human corticospinal
system is similar to that of monkeys but not to that of rats5. Second,
the corticospinal system is involved in dexterous hand movements
typical of primates6–8. Behavioral assessment of manual dexterity is
more pertinent in monkeys than rodents, the former being capable of
dexterous movements of the ﬁngers, as are humans. Third, neutraliza-
tion of Nogo-A may not only favor sprouting of lesioned axons, but
may also induce unspeciﬁc growth of axons, causing undesired
pathologies. The monkey model offers more possibilities than rodents
to detect such changes of behavior.
Neutralization of Nogo-A was found to promote sprouting of
corticospinal axons in marmosets9. The aim of our study was to
extend these anatomical data to macaque monkeys and assess whether
neutralization of Nogo-A enhances motor recovery after spinal lesion
in primates.
The motoneurons controlling hand muscles in macaque monkeys
are located at the cervical and thoracic levels10 (Supplementary Fig. 1
online). We produced deﬁcits in manual dexterity in 12 monkeys by
unilateral cervical cord lesion at the C7-C8 border, rostral to the hand
motoneurons (Supplementary Fig. 1, Supplementary Methods and
Supplementary Table 1 online), aimed unilaterally at the dorsolateral
funiculus, which was completely interrupted in eight monkeys. In four
monkeys, the lesion was incomplete, with a few corticospinal axons
preserved in the dorsolateral funiculus. The monkeys exhibited sub-
stantial postlesion loss of manual dexterity ipsilesionally, accompanied
by hindlimb dysfunction.
The deﬁcit in manual dexterity was followed by a progressive
recovery. However, in a ﬁrst ‘pair’ of monkeys (Fig. 1a) subjected to
a large lesion, recovery was fast and complete in the Nogo-A–speciﬁc
antibody–treated monkey (Mk-AM), in contrast to the control
antibody–treated monkey (Mk-CH). In a second pair of monkeys
(Fig. 1b), the Nogo-A–speciﬁc antibody–treated monkey (Mk-AC)
had a larger lesion but exhibited faster recovery than the control
antibody–treated monkey (Mk-CG). Similarly, in a third pair of
monkeys (Fig. 1c), the Nogo-A–speciﬁc antibody–treated monkey
(Mk-AF) recovered better than the control antibody–treated monkey
(Mk-CS). The functional recovery, plotted as a function of lesion
extent (Fig. 1d), was signiﬁcantly higher in the Nogo-A–speciﬁc
antibody–treated monkeys than in control antibody–treated monkeys
(P ¼ 0.037). In monkeys treated with Nogo-A–speciﬁc antibody, the
recovery was complete (or nearly so) irrespective of lesion extent,
whereas in control-antibody treated monkeys there was an inverse
correlation between lesion extent and functional recovery (Supple-
mentary Fig. 1).
Based on a ‘reach and grasp drawer’ test (Supplementary Fig. 2
online) assessing ability to generate force with the ﬁngers, the
Nogo-A–speciﬁc antibody–treated monkeys tended to recover the
capacity to pull the drawer faster than the control antibody–treated
monkeys (P ¼ 0.27), especially in case of large lesions (Fig. 2a).
The difference was statistically signiﬁcant when excluding the monkey
Mk-CP, which had an incomplete lesion of the dorsolateral funiculus
(P ¼ 0.05). Whether and how a monkey could catch an object thrown
to it (‘ballistic arm movements’ test; Supplementary Fig. 2) also
indicated faster recovery of the capacity to preshape the hand (exten-
sion of ﬁngers) in the Nogo-A–speciﬁc antibody–treated monkeys
(Fig. 2b). This was a trend; however, it was not statistically signiﬁcant
(P¼ 0.12 without monkey Mk-CP). We saw no difference between the
two groups of monkeys regarding capacity of prehension with the
hindlimb (Supplementary Fig. 2).
We labeled corticospinal axons by injecting the anterograde tracer
biotinylated dextran amine (BDA) in the contralesional motor cortex
(Supplementary Fig. 1). In the pair of monkeys Mk-CH and Mk-AM,
corticospinal axonal arbors were more numerous caudal to the
lesion in the Nogo-A–speciﬁc antibody–treated than in the
control antibody–treated monkey (Fig. 2c,d). After normalization
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(Supplementary Table 1 and Supplementary Fig. 3 online), in six
monkeys with complete corticospinal transection in which BDA-
labeling data could be quantiﬁed caudal to the lesion, the normalized
cumulated axonal arbor length was larger in the Nogo-A–speciﬁc
antibody–treated than in the control antibody–treated monkeys
(Fig. 2e). This was a trend; however, it was not statistically signiﬁcant
(P ¼ 0.12). The normalized number of corticospinal axonal swellings
caudal to the lesion was signiﬁcantly larger (Fig. 2f) in the Nogo-A–
speciﬁc antibody–treated than in the control antibody–treated mon-
keys with complete lesion (P o 0.05; if monkey Mk-CP is included,
the difference is not statistically signiﬁcant, P¼ 0.29). Accordingly, the
normalized number of axonal swellings plotted as a function of
normalized axonal arbor length was higher in the Nogo-A–speciﬁc
antibody–treated monkeys (Fig. 2g). We observed sprouting for
a total distance of about 10–12 mm and it occurred from axoto-
mized corticospinal axons (Supplementary Fig. 1) but sprouting
from intact corticospinal axons from both hemispheres may also
have occurred.
The monkeys treated with Nogo-A–speciﬁc antibody did not lose
weight (Supplementary Fig. 3) and remained cooperative with the
experimenter. Furthermore, the monkeys did not show signs of
discomfort or pain when the experimenter touched their bodies or
manipulated their limbs. These observations suggest that the rewiring
induced by the Nogo-A–speciﬁc antibody treatment did not generate
chronic pain (Supplementary Note online).
Neutralization of Nogo-A promotes regrowth of corticospinal (and
possibly other) axons around the lesion and into the denervated spinal
cord in macaque monkeys, in line with previous observation in
marmosets9. For the ﬁrst time in primates, Nogo-A–speciﬁc antibody
treatment also led to considerable functional recovery. The time course
and extent of spontaneous recovery of manual dexterity in the control
antibody–treated monkeys are consistent with earlier reports for
monkeys subjected to C3–C5 level lesion11–13. This time course was
shortened and the recovery of skilled hand function was nearly
complete when neutralizing Nogo-A (Figs. 1 and 2). Neutralization
of Nogo-A by speciﬁc antibodies infused intrathecally led to extensive
functional recovery and enhanced regenerative axonal sprouting and
elongation not only in spinal cord–lesioned adult rats but also in adult
primates, in the absence of detectable malfunctions. These observa-
tions represent an important proof of principle on the way to a new
therapy of spinal cord and brain lesions in humans.
The experiments were carried out in accordance with the Guide for
the Care and Use of Laboratory Animals and approved by local (Swiss)
veterinary authorities.
Video sequences illustrating the behavioral tests used here can be
seen at: http://www.unifr.ch/neuro/rouiller/motorcontcadre.htm.
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Figure 1 Quantitative assessment of manual dexterity before and after lesion. To reduce interindividual variability,
we ﬁrst performed direct comparisons between two monkeys, forming a ‘pair’ (Supplementary Methods online).
(a–c) For three pairs of monkeys, comparison of behavioral scores assessing manual dexterity, before and after the
lesion (day 0), derived from the ‘modiﬁed Brinkman board’ task (number of pellets retrieved within 30 s) for the hand
affected by the cervical lesion. The extent of the blue and red zones in the semicircular ﬁgures represents the extent
of the hemicord lesion for each monkey (but does not indicate the location of the lesion). The two monkeys shown in
c were subjected to intracortical stimulation (ICMS), possibly explaining the less prominent recovery than in the other
monkeys. (d) Relationship between the extent of the hemicord lesion and the degree of functional recovery for the
modiﬁed Brinkman board test. Blue circles represent control antibody–treated monkeys, red squares represent
Nogo-A–speciﬁc antibody–treated monkeys. Three monkeys were plotted separately (green symbols) because they had been subjected to extensive ICMS14,15,
which may have reduced their manual capacity. The recovery of manual dexterity was signiﬁcantly higher (Mann-Whitney test, P ¼ 0.028) in the ﬁve
Nogo-A–speciﬁc antibody–treated monkeys than in the four control antibody–treated monkeys. A statistically signiﬁcant difference was also found when all
12 monkeys were included (Mann-Whitney test, P ¼ 0.037). (e) Left hand of a monkey performing the modiﬁed Brinkman board task, using the precision
grip (opposition of thumb and index ﬁnger).
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Figure 2 Nogo-A–speciﬁc antibody enhanced motor recovery and corticospinal axonal sprouting. Days required after lesion to recover the ability to perform
the reach and grasp drawer (a) and ballistic arm movement (b) tasks plotted as a function of lesion extent. Monkey Mk-AF was not tested before 30 d for
technical reasons. In monkey Mk-CP (indicated by an asterisk), the dorsolateral funiculus was not completely interrupted, possibly explaining the rapid
recovery. Two monkeys did not recover during the 3 months of observation (indicated by plus signs). (c,d) Corticospinal axons were labeled by multiple,
widespread BDA injections in the contralesional motor cortex. In two monkeys, in which all labeled corticospinal axons were interrupted, BDA-labeled axonal
arbors caudal to the lesion were more numerous in the Nogo-A–speciﬁc antibody–treated (Mk-AM; d) than in the control antibody–treated monkey (Mk-CH;
c). The gray area rostral to the lesion delineates the gray matter. In the seven monkeys for which we quantitatively analyzed BDA labeling caudal to the
lesion, the normalized cumulative corticospinal axonal arbor length (mm) and the normalized number of axonal swellings emitted by corticospinal axons
(representing putative re-established contacts with interneurons or motoneurons deprived of inputs as a result of the lesion) were plotted as a function of
lesion extent (e,f). Monkey Mk-CP, with incomplete section of the dorsolateral funiculus (indicated by an asterisk), had profuse sprouting from spared
corticospinal axons. The number of corticospinal axonal swellings was plotted as a function of the cumulative corticospinal axonal arbor length (in mm) for
the seven monkeys (g). Blue circles, control antibody–treated monkeys; red squares, Nogo-A–speciﬁc antibody–treated monkeys. Two monkeys were plotted
separately (green symbols) because they had been subjected to extensive ICMS. The extent of the blue and red zones in the semicircular ﬁgures represents
the extent of the hemicord lesion.
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